Health Stocks in Motion
Updated from 2:46 p.m. EST
Shares of Ligand Pharmaceuticals (LGND) were among the worst-performing health-related stocks Thursday after the company delayed the filing of its annual report because its audit committee needs more time to review issues related to the way the company accounts for product sales and returns.
Ligand said the review is expected to focus on the company's revenue recognition policies and practices for current as well as past reporting periods. The company is also reviewing the accounting and classification of its sales of royalty rights. The audit committee is working as quickly as possible to complete the review but Ligand said that it couldn't estimate when the 2004 audit will be completed.
As a result, Ligand has notified the Securities and Exchange Commission and Nasdaq that its annual report will be delayed until the review is finished. Since the company has not sought a 15-day extension to file its 10-K, and because the company does not believe that it will be filed by March 31, Ligand is no longer in compliance with continued Nasdaq listing requirements, it said. The company plans to meet with a Nasdaq panel regarding its compliance with listing standards. Shares, which had fallen by almost 43% earlier in the trading session, traded down $1.12, or 12.6%, to $7.75.Gene Logic (GLGC) fell 6% after the company said that it would post a 2005 loss that could be as high as $28 million. Gene Logic said that it expects to post a loss of $26 million to $28 million on sales of $83.5 million to $85.5 million. The company plans to invest about $14 million to develop its drug repositioning and selection business, an area of interest, the company said, for pharmaceutical customers. Despite the 2005 forecast, the company did say that it expects to post a profit during 2007 on sales that will exceed $100 million. Gene Logic expects to have about $70 million to $75 million in cash at the end of 2005 and expects to generate cash in 2007. Shares traded down 21 cents to $3.28.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV